Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Malignant Disease × Paclitaxel × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 230 Breast Neoplasms 186 Ovarian Neoplasms 110 Neoplasms 100 Neoplasm Metastasis 58 Lung Neoplasms 54 Fallopian Tube Neoplasms 45 Triple Negative Breast Neoplasms 44 Stomach Neoplasms 41 Parkinson Disease 4, Autosomal Dominant Lewy Body 41 Endometrial Neoplasms 36 Carcinoma, Ovarian Epithelial 31 Squamous Cell Carcinoma of Head and Neck 28 Uterine Cervical Neoplasms 24 Esophageal Neoplasms 21 Carcinoma 21 Colorectal Neoplasms 20 Recurrence 19 Melanoma 18 Small Cell Lung Carcinoma 16 Pancreatic Neoplasms 16 Esophageal Squamous Cell Carcinoma 16 Head and Neck Neoplasms 14 Solid Tumors 12 Adenocarcinoma 12 Carcinoma, Renal Cell 10 Advanced Solid Tumors 10 Carcinoma, Squamous Cell 9 Urinary Bladder Neoplasms 8 Solid Tumor 8

Interventions

amuvatinib 1 Topotecan 1 Paclitaxel 1 Etoposide 1 Erlotinib Hydrochloride 1 Docetaxel 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00881166 2024-08-02

SGI-0470-02

Astex Pharmaceuticals, Inc.

Phase 1 Completed

Malignant Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡